Compare Enveric Biosciences Inc (ENVB) vs Sibanye Stillwater Ltd (SBSW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Sibanye Stillwater Ltd — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.69M), while Sibanye Stillwater Ltd trades at $10.18 (market cap $6.89B). The key difference: Sibanye Stillwater Ltd is far larger — about 1029.9× Enveric Biosciences Inc's market cap, and Sibanye Stillwater Ltd pays a 8.36% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Sibanye Stillwater Ltd for 51 Days on average.
| ENVB | SBSW | |
|---|---|---|
Market Cap | $6.69M | $6.89B |
Volume | 41,141 | 5,024,779 |
Sector | Health | Basic Materials |
52-Week High | $10.80 | $21.12 |
52-Week Low | $1.27 | $8.00 |
Typical Hold Time | 14 Days | 51 Days |
Enterprise Value | -$1.60M | $7.79B |
Dividend Yield | — | 8.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495, up 1.7% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten EPS expectations. Recent news includes a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in an investment conference.
The outlook remains speculative given the lack of revenue and negative profitability, but analyst consensus is bullish with 75% buy ratings. Key risks include the pre-revenue biotech model and dependence on successful drug development. Upside potential hinges on clinical progress and regulatory milestones for its psychiatric therapeutics pipeline.
Sibanye Stillwater (SBSW) trades at $9.91, down 1.0% on the day, with a bearish technical signal from moving averages and oscillators. Fundamentally, the company reported a net loss of $5.17 billion in 2025 despite revenue of $129.68 billion, though 2026 projections show a return to profitability. Recent news highlights strong first-half 2026 results, including 54% revenue growth and a 111% surge in EBITDA, signaling a potential operational turnaround.
The outlook is mixed: analyst consensus is a 'Buy' with a $14.25 price target, implying significant upside, but risks include volatile commodity prices, high debt levels, and inconsistent earnings history. The stock offers value with low P/E and P/S ratios, yet investors must weigh the bullish analyst sentiment against underlying financial volatility and macroeconomic pressures on mining sectors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Sibanye Stillwater Ltd
Sibanye Stillwater Ltd is a South Africa-focused mining company. The Group currently owns and operates five underground and surface gold operations in South Africa: the Cooke, DRDGOLD, Driefontein, and Kloof operations in the West Witwatersrand region, and the Beatrix Operation in the southern Free State province. In addition to mining, the company owns and manages extraction and processing facilities at its operations, where gold-bearing ore is treated and beneficiated to produce gold dore. The gold dore is further refined at Rand Refinery into gold bars with a purity of at least 99.5% and is then sold on international markets. Sibanye holds a 44% interest in Rand Refinery, global refiners of gold, and the largest in Africa. Rand Refinery markets gold to customers around the world.
Read more on SBSW →
